Last updated on October 2018

Tysabri Observational Program


Brief description of study

The primary objective of this study is to assess the long-term safety and impact on disease activity and progression of natalizumab in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.

Detailed Study Description

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment on disability in particular by comparing the results with prospectively determined controls from established databases.

Clinical Study Identifier: NCT00493298

Contact Investigators or Research Sites near you

Start Over

US Biogen Clinical Trial Center

Research site
Prague 10, Czechia
  Connect »

US Biogen Clinical Trial Center

Research site
Prague, Czechia
1.18miles
  Connect »

US Biogen Clinical Trial Center

Research site
Praha 5, Czechia
4.05miles
  Connect »

US Biogen Clinical Trial Center

Research site
Prague 4, Czechia
4.28miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.